$4.05
+0.22 (+5.74%)
USD · as of 2026-08-18 · marketstack
Clinical trials
catalyst calendar across sponsors →Studies where ADAG is the lead sponsor, as filed with ClinicalTrials.gov. Completion dates are the sponsor's own projected windows and are revised as a study runs. Active studies first, then completed and stopped — newest readout first within each.
7 interventional
Held by 5 tracked-famous managers (CITADEL ADVISORS LLC, RENAISSANCE TECHNOLOGIES LLC, MARSHALL WACE, LLP, JANE STREET GROUP, LLC, TWO SIGMA INVESTMENTS, LP) · FINRA short interest 11.4 days to cover (settled 2026-07-31) · government filings 180d: none disclosed
| Study | Phase | Status | Interventions | Conditions | Enrollment | Primary completion | Readout in | Updated |
|---|---|---|---|---|---|---|---|---|
| ADG126 in Combination With Pembrolizumab in Patients With Advanced/Metastatic Solid TumorsNCT05405595Maximum tolerated dose (MTD) and RP2D for ADG126 in combination with pembrolizumab.Randomized · Open-label · Treatment | Phase 1/2 | Recruiting | Drug: ADG126, Pembrolizumab (KEYTRUDA®), Standard of Care (Trifluridine/Tipiracil-Bevacizumab), Standard of care (Fruquintinib) | Advanced/Metastatic Solid Tumors | 186 | 2026-10-31 | in 73 d | 2026-01-07 |
| Study of ADG206 in Subjects With Advanced/Metastatic Solid TumorsNCT05614258Number of participants experiencing dose-limiting toxicities escalating dose levelsOpen-label · Treatment | Phase 1 | Active, not recruiting | Drug: ADG206 | Advanced/Metastatic Solid Tumors | 14 | 2025-06-25actual | — | 2026-01-08 |
| ADG126, ADG126 in Combination With Anti PD1 Antibody, and ADG126 in Combination With ADG106 in Advanced/Metastatic Solid TumorsNCT04645069Number of participants experiencing dose-limiting toxicities escalating dose levels in adults with advanced / metastatic solid tumorsNon-randomized · Open-label · Treatment | Phase 1/2 | Completed | Biological: ADG126 Mono, ADG126-anti PD1, ADG126-ADG106 | Advanced/Metastatic Solid Tumors | 58 | 2024-01-29actual | — | 2024-08-14 |
| A Phase 1b/2 Study of ADG116, ADG116 Combined With Anti-PD-1 Antibody or Anti-CD137 Antibody in Solid Tumors PatientsNCT04501276Number of participants experiencing dose-limiting toxicities escalating dose levels in adults with advanced / metastatic solid tumorsNon-randomized · Open-label · Treatment | Phase 1 | Completed | Drug: ADG116, ADG106, anti PD1 drug | Advanced/Metastatic Solid Tumors | 72 | 2024-01-17actual | — | 2026-01-08 |
| ADG116 in Combination With Pembrolizumab in Patients With Advanced/Metastatic Solid TumorsNCT05277402Dose-limiting toxicity (DLT) and RP2D of ADG116 in combination with pembrolizumab.Open-label · Treatment | Phase 1 | Completed | Drug: ADG116 | Advanced/Metastatic Solid Tumors | 6 | 2022-08-01actual | — | 2024-02-26 |
| Study of CD137 Agonist ADG106 With Advanced or Metastatic Solid Tumors and/or Non-Hodgkin LymphomaNCT03707093Number of participants experiencing dose-limiting toxicitiesOpen-label · Treatment | Phase 1 | Completed | Drug: ADG106 | Solid Tumors, Non-Hodgkin Lymphoma | 49 | 2022-01-24actual | — | 2022-10-18 |
| Study of ADG116 in Patients With Advanced/Metastatic Solid TumorsNCT04111445Number of participants experiencing dose-limiting toxicitiesOpen-label · Treatment | Phase 1 | Terminatedsponsor's stated reason: Study discontinued due to business decision. | Drug: ADG116 | Solid Tumor | 1 | 2021-04-27actual | — | 2021-09-10 |
Primary completion is the date the sponsor filed with the registry — their own projection, revised whenever they revise it, unless the row is marked actual.
Source: ClinicalTrials.gov, retrieved 2026-08-19